Insider Buying: Fennec Pharmaceuticals Inc. (TSE:FRX) Director Buys 15,000 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Jeffrey Hackman purchased 15,000 shares of the stock in a transaction on Monday, May 19th. The shares were purchased at an average price of C$9.77 per share, for a total transaction of C$146,580.00.

Fennec Pharmaceuticals Trading Up 9.7%

TSE FRX opened at C$9.50 on Tuesday. The stock’s 50-day simple moving average is C$8.25 and its two-hundred day simple moving average is C$8.44. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$10.14. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$183.20 million, a price-to-earnings ratio of -160.93 and a beta of 0.25.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.